Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

被引：7

作者：

O'Mahony, Denise G. ^{[1
,2
]}

Ramus, Susan J. ^{[3
,4
]}

Southey, Melissa C. ^{[5
,6
,7
]}

Meagher, Nicola S. ^{[3
,4
,8
]}

Hadjisavvas, Andreas ^{[2
]}

John, Esther M. ^{[9
,10
]}

Hamann, Ute ^{[11
]}

Imyanitov, Evgeny N. ^{[12
]}

Andrulis, Irene L. ^{[13
,14
]}

Sharma, Priyanka ^{[15
]}

Daly, Mary B. ^{[16
]}

Hake, Christopher R. ^{[17
]}

Weitzel, Jeffrey N. ^{[18
]}

Jakubowska, Anna ^{[19
,20
]}

Godwin, Andrew K. ^{[21
]}

Arason, Adalgeir ^{[22
,23
]}

Bane, Anita ^{[24
,25
]}

Simard, Jacques ^{[26
]}

Soucy, Penny ^{[26
]}

Caligo, Maria A. ^{[27
]}

Mai, Phuong L. ^{[28
]}

Claes, Kathleen B. M. ^{[29
]}

Teixeira, Manuel R. ^{[30
,31
,32
]}

Chung, Wendy K. ^{[33
,34
]}

Lazaro, Conxi ^{[35
]}

Hulick, Peter J. ^{[36
,37
]}

Toland, Amanda E. ^{[38
]}

Pedersen, Inge Sokilde ^{[39
,40
,41
]}

Neuhausen, Susan L. ^{[42
]}

Vega, Ana ^{[43
,44
,45
]}

de la Hoya, Miguel ^{[46
]}

Nevanlinna, Heli ^{[47
]}

Dhawan, Mallika ^{[48
]}

Zampiga, Valentina ^{[49
]}

Danesi, Rita ^{[50
]}

Varesco, Liliana ^{[51
]}

Gismondi, Viviana ^{[51
]}

Vellone, Valerio Gaetano ^{[52
]}

James, Paul A. ^{[53
]}

Janavicius, Ramunas ^{[54
,55
]}

Nikitina-Zake, Liene ^{[56
]}

Nielsen, Finn Cilius ^{[57
]}

van Overeem Hansen, Thomas ^{[58
,59
]}

Pejovic, Tanja ^{[60
,61
]}

Borg, Ake ^{[62
,63
]}

Rantala, Johanna ^{[64
]}

Offit, Kenneth ^{[65
,66
]}

Montagna, Marco ^{[67
]}

Nathanson, Katherine L. ^{[68
]}

Domchek, Susan M. ^{[68
]}

机构：

[1] Cyprus Inst Neurol & Genet, Biostat Unit, CY-2371 Nicosia, Cyprus

[2] Cyprus Inst Neurol & Genet, Dept Canc Genet Therapeut & Ultrastruct Pathol, CY-2371 Nicosia, Cyprus

[3] Univ New South Wales Sydney, Univ New South Wales Med & Hlth, Sch Clin Med, Sydney, NSW 2052, Australia

[4] Univ New South Wales Sydney, Adult Canc Program, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia

[5] Monash Univ, Sch Clin Sci Monash Hlth, Precis Med, Clayton, Vic 3168, Australia

[6] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic 3010, Australia

[7] Canc Council Victoria, Canc Epidemiol Div, Melbourne, Vic 3004, Australia

[8] Univ Sydney, Daffodil Ctr, Sydney, NSW, Australia

[9] Stanford Univ, Sch Med, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA

[10] Stanford Univ, Sch Med, Stanford Canc Inst, Dept Med,Div Oncol, Stanford, CA 94304 USA

[11] German Canc Res Ctr, Mol Genet Breast Canc, D-69120 Heidelberg, Germany

[12] NN Petrov Inst Oncol, St Petersburg 197758, Russia

[13] Mt Sinai Hosp, Fred A Litwin Ctr Canc Genet, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada

[14] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada

[15] Univ Kansas, Med Ctr, Div Med Oncol, Dept Internal Med, Westwood, KS 66205 USA

[16] Fox Chase Canc Ctr, Dept Clin Genet, Philadelphia, PA 19111 USA

[17] Waukesha Mem Hosp Pro Hlth Care, Waukesha, WI 53188 USA

[18] Univ Kansas, Ctr Canc, Kansas City, MO 66160 USA

[19] Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, PL-171252 Szczecin, Poland

[20] Pomeranian Med Univ, Independent Lab Mol Biol & Genet Diagnost, PL-171252 Szczecin, Poland

[21] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA

[22] Landspitali Univ Hosp, Dept Pathol, IS-101 Reykjavik, Iceland

[23] Univ Iceland, Fac Med, BMC Biomed Ctr, IS-101 Reykjavik, Iceland

[24] McMaster Univ, Juravinski Hosp, Dept Pathol & Mol Med, Hamilton, ON L8V 1C3, Canada

[25] McMaster Univ, Ctr Canc, Hamilton, ON L8V 1C3, Canada

[26] Univ Laval, Res Ctr, Ctr Hosp Univ Quebec, Genom Ctr, Quebec City, PQ G1V 4G2, Canada

[27] Univ Hosp, SOD Genet Mol, I-56126 Pisa, Italy

[28] Univ Pittsburgh, Sch Med, Magee Womens Hosp, Pittsburgh, PA 15213 USA

[29] Univ Ghent, Ctr Med Genet, B-9000 Ghent, Belgium

[30] Portuguese Oncol Inst Porto, Ctr Comprehens Canc, Dept Lab Genet, P-4200072 Porto, Portugal

[31] Univ Porto, Sch Med, P-4050013 Porto, Portugal

[32] Univ Porto, Biomed Sci Inst ICBAS, P-4050013 Porto, Portugal

[33] Columbia Univ, Dept Pediat, New York, NY 10032 USA

[34] Columbia Univ, Dept Med, New York, NY 10032 USA

[35] CIBERONC, Catalan Inst Oncol, Hereditary Canc Program, ONCOBELL IDIBELL IGTP, Barcelona 08908, Spain

[36] NorthShore Univ HealthSyst, Ctr Med Genet, Evanston, IL 60201 USA

[37] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA

[38] Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA

[39] Aalborg Univ Hosp, Mol Diagnost, DK-9000 Aalborg, Denmark

[40] Aalborg Univ Hosp, Clin Canc Res Ctr, DK-9000 Aalborg, Denmark

[41] Aalborg Univ, Dept Clin Med, DK-9000 Aalborg, Denmark

[42] Beckman Res Inst City Hope, Dept Populat Sci, Duarte, CA 91010 USA

[43] Ctr Invest Red Enfermedades Raras CIBERER, Madrid 28029, Spain

[44] Fdn Publ Galega Med Xenom, Santiago De Compostela 15706, Spain

[45] Complejo Hosp Univ Santiago, SERGAS, Inst Invest Sanitaria Santiago de Compostela IDIS, Santiago De Compostela 15706, Spain

[46] IdISSC Inst Invest Sanitaria Hosp Clin San Carlos, Hosp Clin San Carlos, Mol Oncol Lab, CIBERONC, Madrid 28040, Spain

[47] Univ Helsinki, Helsinki Univ Hosp, Dept Obstet & Gynecol, Helsinki 00290, Finland

[48] Univ Calif San Francisco, Canc Genet & Prevent Program, San Francisco, CA 94143 USA

[49] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Biosci Lab, Meldola, Italy

[50] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Romagna Canc Registry, I-47014 Meldola, Italy

来源：

BRITISH JOURNAL OF CANCER | 2023年 / 128卷 / 12期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会; 芬兰科学院; 加拿大健康研究院; 美国国家卫生研究院; 俄罗斯科学基金会;

关键词：

GERMLINE MUTATIONS; UNCERTAIN SIGNIFICANCE; CLINICAL-SIGNIFICANCE; UNKNOWN SIGNIFICANCE; SEQUENCE VARIANTS; CARCINOMA; RECOMMENDATIONS; FREQUENCY; SERIES; CLASSIFICATION;

D O I：

10.1038/s41416-023-02263-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundThe distribution of ovarian tumour characteristics differs between germline BRCA1 and BRCA2 pathogenic variant carriers and non-carriers. In this study, we assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity, for application using the American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) variant classification system.MethodsData for 10,373 ovarian cancer cases, including carriers and non-carriers of BRCA1 or BRCA2 pathogenic variants, were collected from unpublished international cohorts and consortia and published studies. Likelihood ratios (LR) were calculated for the association of ovarian cancer histology and other characteristics, with BRCA1 and BRCA2 variant pathogenicity. Estimates were aligned to ACMG/AMP code strengths (supporting, moderate, strong).ResultsNo histological subtype provided informative ACMG/AMP evidence in favour of BRCA1 and BRCA2 variant pathogenicity. Evidence against variant pathogenicity was estimated for the mucinous and clear cell histologies (supporting) and borderline cases (moderate). Refined associations are provided according to tumour grade, invasion and age at diagnosis.ConclusionsWe provide detailed estimates for predicting BRCA1 and BRCA2 variant pathogenicity based on ovarian tumour characteristics. This evidence can be combined with other variant information under the ACMG/AMP classification system, to improve classification and carrier clinical management.

引用

页码：2283 / 2294

页数：12

共 50 条

[31] Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2
Hoang, Lien N.
Gilks, Blake C.
ADVANCES IN ANATOMIC PATHOLOGY, 2018, 25 (02) : 85 - 95
[32] Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
Samuel, David
Diaz-Barbe, Alexandra
Pinto, Andre
Schlumbrecht, Matthew
George, Sophia
CELLS, 2022, 11 (03)
[33] BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific
Cifuentes-C, Laura
Lucia Rivera-Herrera, Ana
Barreto, Guillermo
COLOMBIA MEDICA, 2019, 50 (03): : 163 - 175
[34] BRCA1 and BRCA2 mutations and the risk for colorectal cancer
Sopik, V.
Phelan, C.
Cybulski, C.
Narod, S. A.
CLINICAL GENETICS, 2015, 87 (05) : 411 - 418
[35] Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers
Krammer, Julia
Pinker-Domenig, Katja
Robson, Mark E.
Gonen, Mithat
Bernard-Davila, Blanca
Morris, Elizabeth A.
Mangino, Debra A.
Jochelson, Maxine S.
BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 565 - 571
[36] Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
Silvestri, Valentina
Barrowdale, Daniel
Mulligan, Anna Marie
Neuhausen, Susan L.
Fox, Stephen
Karlan, Beth Y.
Mitchell, Gillian
James, Paul
Thull, Darcy L.
Zorn, Kristin K.
Carter, Natalie J.
Nathanson, Katherine L.
Dornchek, Susan M.
Rebbeck, Timothy R.
Ramus, Susan J.
Nussbaum, Robert L.
Olopade, Olufunrnilayo I.
Rantala, Johanna
Yoon, Sook-Yee
Caligo, Maria A.
Spugnesi, Laura
Bojesen, Anders
Pedersen, Inge Sokilde
Thomassen, Muds
Jensen, Uffe Birk
Toland, Amanda Ewart
Senter, Leigha
Andrulis, Irene L.
Glendon, Gord
Hulick, Peter J.
Irnyanitov, Evgeny N.
Greene, Mark H.
Mai, Phuong L.
Singer, Christian F.
Rappaport-Fuerhauser, Christine
Kramer, Gero
Vijai, Joseph
Offit, Kenneth
Robson, Mark
Lincoln, Anne
Jacobs, Lauren
Machackova, Eva
Foretova, Lenka
Navratilova, Marie
Vasickova, Petra
Couch, Fergus J.
Hallberg, Emily
Ruddy, Kathryn J.
Sharma, Priyanka
Kim, Sung-Won
BREAST CANCER RESEARCH, 2016, 18
[37] Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
Kotsopoulos, Joanne
Gronwald, Jacek
McCuaig, Jeanna M.
Karlan, Beth Y.
Eisen, Andrea
Tung, Nadine
Bordeleau, Louise
Senter, Leigha
Eng, Charis
Couch, Fergus
Fruscio, Robert
Weitzel, Jeffrey N.
Olopade, Olufunmilayo
Singer, Christian F.
Pal, Tuya
Foulkes, William D.
Neuhausen, Susan L.
Sun, Ping
Lubinski, Jan
Narod, Steven A.
Huzarski, Tomasz
Cybulski, Cezary
Rosen, Barry
Sweet, Kevin
Zakalik, Dana
Wood, Marie
McKinnon, Wendy
Elser, Christine
Wiesner, Georgia
Friedman, Eitan
Meschino, Wendy
Snyder, Carrie
Metcalfe, Kelly
Poll, Aletta
Warner, Ellen
Kim, Raymond
Armel, Susan
Demsky, Rochelle
Ainsworth, Peter
Steele, Linda
Saal, Howard
Serfas, Kim
Panchal, Seema
Cullinane, Carey A.
Reilly, Robert E.
Blum, Joanne L.
Kwong, Ava
Rayson, Daniel
Ramon y Cajal, Teresa
Dungan, Jeffrey
GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 820 - 826
[38] Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
Moran, A.
O'Hara, C.
Khan, S.
Shack, L.
Woodward, E.
Maher, E. R.
Lalloo, F.
Evans, D. G. R.
FAMILIAL CANCER, 2012, 11 (02) : 235 - 242
[39] BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
Kitson, Sarah J.
Bafligil, Cemsel
Ryan, Neil A. J.
Lalloo, Fiona
Woodward, Emma R.
Clayton, Richard D.
Edmondson, Richard J.
Bolton, James
Crosbie, Emma J.
Evans, D. Gareth
EUROPEAN JOURNAL OF CANCER, 2020, 136 : 169 - 175
[40] Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
Rebbeck, Timothy R.
Mitra, Nandita
Wan, Fei
Sinilnikova, Olga M.
Healey, Sue
McGuffog, Lesley
Mazoyer, Sylvie
Chenevix-Trench, Georgia
Easton, Douglas F.
Antoniou, Antonis C.
Nathanson, Katherine L.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (13): : 1347 - 1361

← 1 2 3 4 5 →